Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Patent
1998-06-22
2000-08-08
Higel, Floyd D.
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
544328, 544331, C07D40114, C07D41314
Patent
active
061003999
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to a novel method for synthesizing imidazole derivatives having 4-aryl, 5-pyrimidine heterocyclic rings.
BACKGROUND OF THE INVENTION
The present invention describes a novel, and general method to prepared 5-pyrimidinyl substituted imidazoles. Previous syntheses of this class of molecules utilized the van Leusen reaction (van Leusen, A. M., et. al. J. Org. Chem. 1977, 42, 1153), which involves the cycloaddition of an imine and a tosylisonitrile. Difficulties in preparing the aldehyde precursors to the desired imines limited the scope of this approach. In Adams et al., WO 95/02591 an improvement on the cycloaddition reaction is shown for similar compounds. However addition of a pyrimidine ring in an environmentally favourable and commercially feasible manner is still needed. The present invention employs a novel method of cycloaddition of a tosylisonitrile with an .alpha.-ketoaldimine to produce a 5-keto imidazole derivative. The 5-keto group serves as an excellent precursor for addition of the optionally substituted pyrimidine ring.
SUMMARY OF THE INVENTION
The present invention is to a process of making compounds of Formula (I), ##STR1## wherein
R.sub.1 is an optionally substituted pyrimidin-4-yl ring;
R.sub.4 is an optionally substituted phenyl, naphth-1-yl or naphth-2-yl, or heteroaryl ring;
m is 0, or the integer 1 or 2;
m' is an integer having a value of 1 or 2,
R.sub.2 is --(CR.sub.10 R.sub.20).sub.n' OR.sub.9, heterocyclyl, heterocyclylC.sub.1-10 alkyl, C.sub.1-10 alkyl, halo-substituted C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-10 alkyl, C.sub.5-7 cycloalkenyl, C.sub.5-7 cycloalkenyl-C.sub.1-10 -alkyl, aryl, arylC.sub.1-10 alkyl, heteroaryl, heteroaryl-C.sub.1-10 -alkyl, (CR.sub.10 R.sub.20).sub.n OR11, (CR.sub.10 R.sub.20).sub.n S(O).sub.m R.sub.18, (CR.sub.10 R.sub.20).sub.n NHS(O).sub.2 R.sub.18, (CR.sub.10 R.sub.20).sub.n NR.sub.13 R.sub.14, (CR.sub.10 R.sub.20).sub.n NO.sub.2, (CR.sub.10 R.sub.20).sub.n CN, (CR.sub.10 R.sub.20).sub.n' SO.sub.2 R.sub.18, (CR.sub.10 R.sub.20).sub.n S(O).sub.m' NR.sub.13 R.sub.14, (CR.sub.10 R.sub.20).sub.n C(Z)R.sub.11, (CR.sub.10 R.sub.20).sub.n OC(Z)R.sub.11, (CR.sub.10 R.sub.20).sub.n C(Z)OR.sub.11, (CR.sub.10 R.sub.20).sub.n C(Z)NR.sub.13 R.sub.14, (CR.sub.10 R.sub.20).sub.n C(Z)NR.sub.11 OR.sub.9, (CR.sub.10 R.sub.20).sub.n NR.sub.10 C(Z)R.sub.11, (CR.sub.10 R.sub.20 (.sub.n NR.sub.10 C(Z)NR.sub.13 R.sub.14, (CR.sub.10 R.sub.20).sub.n N(OR.sub.6)C(Z)NR.sub.13 R.sub.14, (CR.sub.10 R.sub.20).sub.n N(OR.sub.6)C(Z)R.sub.11, (CR.sub.10 R.sub.20).sub.n C(.dbd.NOR.sub.6)R.sub.11, (CR.sub.10 R.sub.20).sub.n NR.sub.10 C(.dbd.NR.sub.19)NR.sub.13 R.sub.14, (CR.sub.10 R.sub.20).sub.n OC(Z)NR.sub.13 R.sub.14, (CR.sub.10 R.sub.20).sub.n NR.sub.10 C(Z)NR.sub.13 R.sub.14, (CR.sub.10 R.sub.20).sub.n NR.sub.10 C(Z)OR.sub.10, 5-(R.sub.18)-1,2,4-oxadizaol-3-yl or 4-(R.sub.12)-5-(R.sub.18 R.sub.19)-4,5-dihydro-1,2,4-oxadiazol-3-yl; wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl groups may be optionally substituted;
n is an integer having a value of 1 to 10;
n' is 0, or an integer having a value of 1 to 10;
Z is oxygen or sulfur;
R.sub.3 is heterocyclyl, heterocyclylC.sub.1-10 alkyl or R.sub.8 ;
R.sub.6 is hydrogen, a pharmaceutically acceptable cation, C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, aryl, arylC.sub.1-4 alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, aroyl, or C.sub.1-10 alkanoyl;
R.sub.8 is C.sub.1-10 alkyl, halo-substituted C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.5-7 cycloalkenyl, aryl, arylC.sub.1-10 alkyl, heteroaryl, heteroarylC.sub.1-10 alkyl, (CR.sub.10 R.sub.20).sub.n OR.sub.11, (CR.sub.10 R.sub.20).sub.n S(O).sub.m R.sub.18, (CR.sub.10 R.sub.20).sub.n NHS(O).sub.2 R.sub.18, (CR.sub.10 R.sub.20).sub.n NR.sub.13 R.sub.14 ; wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl may be optionally substituted;
R.sub.9 is hydrogen, --C(Z)R.sub.11
REFERENCES:
patent: 2748119 (1956-05-01), Rorig
patent: 3557114 (1971-01-01), Bicking
patent: 3707475 (1972-12-01), Lombardino
patent: 3772441 (1973-11-01), Lombardino
patent: 3929807 (1975-12-01), Fitzi
patent: 3940486 (1976-02-01), Fitzi
patent: 4058614 (1977-11-01), Baldwin
patent: 4199592 (1980-04-01), Cherkofsky
patent: 4447431 (1984-05-01), Sallmann
patent: 4503065 (1985-03-01), Wilkerson
patent: 4565875 (1986-01-01), Cavender
patent: 4686231 (1987-08-01), Bender et al.
patent: 4822805 (1989-04-01), Tasasugi et al.
patent: 5096915 (1992-03-01), Parsons et al.
patent: 5234917 (1993-08-01), Finkelstein et al.
patent: 5312828 (1994-05-01), Finkelstein et al.
patent: 5593991 (1997-01-01), Adams et al.
patent: 5593992 (1997-01-01), Adams et al.
patent: 5656644 (1997-08-01), Adams et al.
patent: 5658903 (1997-08-01), Adams et al.
patent: 5663334 (1997-09-01), Sheldrake et al.
patent: 5670527 (1997-09-01), Adams et al.
patent: 5686455 (1997-11-01), Adams et al.
patent: 5739143 (1998-04-01), Adams et al.
patent: 5756499 (1998-05-01), Adams et al.
patent: 5783576 (1998-07-01), Roos et al.
patent: 5869660 (1999-02-01), Adams et al.
Kawasaki et al., J. Bio Chem., 272(30), pp. 18518-18521.
Uno, Bull. Chem. Soc. Japan., vol. 69, pp. 1763-1767 (1996).
Katrutzky, Synthesis, pp. 45-47 (1993).
Johnson, P.A., J.Chem.Soc., Perkin Trans., vol. 1, pp. 895-905 (1996).
Ishibashi, Chem. Pharm. Bull., 37(8), pp. 2214-2216 (1989).
Dinarello et al., Rev.Infect.Disease, 6,p.51 (1984).
Dinarello, J.Clin.Immun., 5(5), p.287-297 (1985).
R.P.Soni, Aust.J.Chem., 35, p.1493-6 (1982).
Poli et al., Proc.Nat'l Acad.Sci., 87, p.782-784 (1990).
VanLeusen et al., J.O.C., 42, p. 1153 (1977).
Kumada et al., Tetrahedron Letters, 22, p.5319 (1981).
Pridgen, J.Org.Chem., 47, p.4319 (1982).
Stille, J.Amer.Chem.Soc., 109, p.5478 (1978).
Fischer et al., Rec.Trav.Chim.Pays.Bas., 84, p.439 (1965).
Snieckus, V., Tetrahedron Letters, 29, 2135 (1988).
Terashimia, M., Chem.Pharm.Bull., 11, p.4755 (1985).
Thompson, W.J., et al., J.Org.Chem., 49, p.5237 (1984).
Garigipati, R., Tetrahedron Letters, 31,p.190 (1989).
Engel & Steglich, Leibigs Ann.Chem., 1916 (1978).
Strzybny et al., J. Org. Chem., 28, p. 3381 (1963).
Zavyalov, et al., Khim Farm Zh, 26(3), p. 88 (1992) (With Translation).
Colotta et al., J. Immunol., 132(2), p. 936 (1984).
Simon et al., J. Immunol. Methods, 84, p. 85 (1985).
Becker et al., J. Immunol., 147, p. 4307 (1991).
Gilbert, Synthesis, pp. 30-32 (1972).
Morton et al., Tetrahedron Letters, 4123 (1982).
Armarego, W. J. Chem. Soc., (JCSOA9) p. 561 (1962).
Dinner Dara L.
Higel Floyd D.
Kinzig Charles M.
SmithKline Beecham Corporation
Venetianer Stephen
LandOfFree
Synthesis for 4-aryl-5-pyrimidine imidazole substituted compound does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis for 4-aryl-5-pyrimidine imidazole substituted compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis for 4-aryl-5-pyrimidine imidazole substituted compound will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1151265